𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Optimal debulking following chemotherapy of advanced-stage epithelial ovarian carcinoma

✍ Scribed by Dr. Benjamin Piura; Marek Glezerman


Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
343 KB
Volume
40
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis


We reviewed the records of 110 consecutive patients with advanced-stage epithelial ovarian carcinoma treated at the Soroka Medical Center, Beer-Sheva, Israel, from 1961-1987. Twenty patients (18.1%) had optimal debulking at initial laparotomy, 30 patients (27.2%) had nonoptimal debulking at initial laparotomy, 20 patients (18.1%) had an "inoperable" disease at initial laparotomy, and 40 patients (36.3%) had such poorly written records that no information about the degree of resectability at initial laparotomy could be obtained. Four patients, in whom the residual tumor left at initial laparotomy had responded to chemotherapy, had a second laparotomy. In all four patients optimal debulking surgery at second laparotomy was easy to perform and was successful. The value of a second laparotomy after a few cycles of chemotherapy in order to optimally debulk the residual tumor left at initial laparotomy is discussed. It is concluded that a second attempt of debulking surgery after chemotherapy has a respectable place in the management of patients with advancedstate epithelial ovarian carcinoma, but further research is needed.


📜 SIMILAR VOLUMES


Prognostic factors for patients with sta
✍ Oliver Zivanovic; Richard R. Barakat; Paul J. Sabbatini; Carol L. Brown; Jason A 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB

## Abstract ## BACKGROUND. The aim was to determine the long‐term outcome for patients with FIGO stage IV epithelial ovarian carcinoma (EOC) treated with intraperitoneal (IP) chemotherapy after second‐look assessment. ## METHODS. By using data from a retrospective cohort of 433 patients who rece

Ten-year follow-up of a phase 2 study of
✍ Gisele A. Sarosy; Mahrukh M. Hussain; Michael V. Seiden; Arlan F. Fuller; Najmos 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 1 views

## Abstract ## BACKGROUND: The objective of this study was to assess activity and toxicity in patients with newly diagnosed, advanced‐stage epithelial ovarian cancer (EOC) who were receiving dose‐intense paclitaxel, cyclophosphamide, cisplatin, and filgrastim delivered with a flexible dosing sched